Veozah (fezolinetant) review: the non-hormonal hot flash option that actually has FDA approval
Veozah is not a supplement and not a hormone — it is a prescription medication with an actual clinical trial record. Here is what the evidence says about how well it works, what it costs, and when it makes sense.
Veozah (fezolinetant) is a legitimate, FDA-approved option for women who cannot or prefer not to use hormone therapy for hot flashes. It works through a completely different mechanism — blocking the neurokinin B pathway in the brain rather than supplementing estrogen — and in its clinical trials (the SKYLIGHT program) it meaningfully reduced hot flash frequency and severity. The serious caveat is real: FDA added a Boxed Warning for rare but serious liver injury, and liver monitoring is required. For the right patient — someone ruled out of HRT, with normal liver function, and moderate-to-severe vasomotor symptoms — Veozah is a genuine medical option, not a supplement or placebo.
What you will actually pay
| Plan | Monthly | Visit fee | Best for |
| Cash pay (no savings program) | ~$550–$778 | Standard office visit copay or telehealth fee | Uninsured or cash-pay patients; verify GoodRx at your pharmacy |
| With GoodRx coupon | from ~$484 | Standard visit fee | Uninsured patients — lowest verified cash price with a discount coupon |
| With manufacturer copay card (commercial insurance)most affordable with insurance | $0 first month, then ~$30 | Standard insurance copay for visit | Commercially insured patients — by far the lowest ongoing cost |
| With commercial insurance (no copay card) | Varies by plan | Standard copay | Women whose insurance covers Veozah without requiring the Astellas savings program |
Estimated all-in cost: ~$360–$400/yr with commercial insurance copay card (~$30/mo after free first month); ~$5,800–$9,300/yr cash pay without any savings program
- ✓ FDA-approved for moderate-to-severe vasomotor symptoms (hot flashes, night sweats)
- ✓ Non-hormonal — meaningful option for women who cannot use estrogen
- ✓ Once-daily oral tablet — simple dosing
- ✓ Covered by approximately 64% of commercial insurance plans
- ✓ Manufacturer copay card brings cost to ~$30/mo for insured patients
- ✓ Clinical trials (SKYLIGHT 1 and 2) showed statistically significant reduction in hot flash frequency and severity
- ⚑ Boxed Warning: rare but serious liver injury — requires baseline and periodic liver function monitoring
- ⚑ Not appropriate for women with liver impairment (Child-Pugh Class B or C)
- ⚑ Cash price without insurance is high ($550–$778/mo)
- ⚑ Not FDA-approved for other menopause symptoms beyond vasomotor symptoms
- ⚑ Does not address bone loss, vaginal atrophy, or other menopause concerns
- ⚑ No generic available; launched 2023 — relatively new
What Veozah is — and what makes it different
Veozah (fezolinetant) is an FDA-approved prescription medication approved in May 2023 for moderate-to-severe vasomotor symptoms — hot flashes and night sweats — from menopause. It is manufactured by Astellas Pharma and taken as a 45mg oral tablet once daily.
What makes it clinically significant is its mechanism: Veozah is a neurokinin 3 (NK3) receptor antagonist. It blocks a neurotransmitter pathway in the hypothalamus — specifically, the neurokinin B (NKB) pathway — that drives the erratic temperature regulation behind hot flashes. It does not contain estrogen, progesterone, or any other hormone. That is not a small point: it means women who cannot or prefer not to use hormone therapy now have an FDA-approved, evidence-backed alternative.
What the clinical trials actually showed
Veozah was studied in the SKYLIGHT program — a series of phase 3 randomized controlled trials. SKYLIGHT 1 and 2 together enrolled over 1,000 women with moderate-to-severe vasomotor symptoms. Key findings:
- Statistically significant reduction in hot flash frequency vs. placebo at weeks 4 and 12
- Meaningful reduction in hot flash severity (severity composite score improved vs. placebo)
- Benefits were durable through 52 weeks in the longer trial
- Discontinuation rates due to adverse events were similar to placebo
To put this in context: 'statistically significant' means the improvement was not attributable to chance. It does not mean every patient responded. In the trials, a meaningful portion of women experienced ≥50% reduction in hot flash frequency — but a portion saw modest improvement or no response. This is consistent with most prescription treatments for vasomotor symptoms, including HRT.
The Boxed Warning: what you need to know
This is the most important thing to understand before starting Veozah. The FDA added a Boxed Warning — the strongest safety label available — for rare but serious liver injury (hepatotoxicity). This warning was added after post-market surveillance identified cases of clinically significant liver enzyme elevations in some patients.
What this means in practice: your prescribing clinician should check your liver function (ALT/AST) before starting Veozah. You should not start it if you have moderate to severe liver impairment. Periodic liver monitoring during treatment is recommended. If you develop symptoms of liver injury — unusual fatigue, jaundice, abdominal pain, dark urine — contact your provider immediately.
This is a real safety consideration, not a legal formality. For women with normal baseline liver function, the absolute risk remains low, but it is not zero. The risk-benefit conversation with your clinician is worth having carefully, particularly if you take other medications with any hepatic metabolism.
Who Veozah actually makes sense for
The clearest use case is a woman with moderate-to-severe hot flashes who cannot or actively prefers not to use hormone therapy. This includes:
- Women with a history of estrogen receptor–positive breast cancer (no hormones available — check with oncologist on Veozah specifically)
- Women with a personal or family history of blood clots (DVT/PE) that makes systemic estrogen higher risk
- Women who have tried HRT and had intolerable side effects
- Women who prefer a non-hormonal approach for any reason
For women who can use hormone therapy, HRT typically has broader efficacy for menopause symptoms overall — it addresses not just hot flashes but also bone density, vaginal atrophy, and mood. Veozah is a specialist tool for a specific symptom, not a replacement for the full hormonal picture.
Cost: what you will actually pay
Without insurance or a savings program, Veozah runs roughly $550–$778 per month. GoodRx brings the cash price down to approximately $484/month at the lowest verified price. These are high for a daily oral medication.
The better news: the Astellas manufacturer copay savings card makes Veozah much more accessible for commercially insured patients. The program provides the first month free and subsequent months at approximately $30/mo. Astellas reports that approximately 64% of commercially insured patients have some level of insurance coverage for Veozah.
Medicare patients have a harder path — manufacturer copay programs do not apply to Medicare, and coverage under Medicare Part D varies. If you are on Medicare, verify your plan's formulary directly before starting.
How to get a prescription
Veozah is a prescription medication. It can be prescribed by an OB/GYN, primary care physician, or any clinician licensed to prescribe in your state. Menopause-specialized telehealth platforms (Midi Health, Alloy) can also prescribe it after a clinical evaluation.
Before writing the prescription, your clinician should review your liver function tests, current medications, and medical history — particularly any liver conditions or concurrent hepatotoxic medications. The prescription can then go to any retail pharmacy or mail-order service.
What Veozah does not do
It is worth being clear about scope. Veozah is approved only for vasomotor symptoms. It does not: prevent bone loss, address vaginal atrophy or GSM (genitourinary syndrome of menopause), improve sleep (beyond the indirect benefit of fewer hot flashes disrupting it), treat mood changes, or reduce cardiovascular risk the way HRT does. For women whose primary symptom is hot flashes and that is the treatment goal, this is the right frame. For a comprehensive menopause treatment, it is not the complete answer.
Frequently asked questions
What is Veozah and how does it work?+–
Veozah (fezolinetant) is an FDA-approved prescription medication for moderate-to-severe vasomotor symptoms (hot flashes and night sweats) from menopause. It works by blocking neurokinin 3 (NK3) receptors in the hypothalamus — the brain's thermoregulatory center — reducing the erratic temperature signals that cause hot flashes. It does not contain any hormones.
Is Veozah safe?+–
For most women with normal liver function, Veozah has been shown to be safe in clinical trials. The key safety concern is rare but serious liver injury — the FDA added a Boxed Warning for this in 2023. Baseline liver function tests are required before starting, and periodic monitoring is recommended during treatment. Women with pre-existing liver disease should not take it.
Does Veozah work as well as HRT for hot flashes?+–
In head-to-head terms, HRT (estrogen therapy) generally shows greater efficacy for hot flash reduction than Veozah. However, for women who cannot or prefer not to use hormones — due to breast cancer history, blood clot risk, or personal preference — Veozah provides a meaningful, evidence-based alternative that works through a completely different mechanism.
How long does it take for Veozah to work?+–
In the SKYLIGHT clinical trials, patients began seeing measurable reductions in hot flash frequency within the first one to two weeks. Meaningful benefit — at least 50% reduction for responding patients — was typically established by week four.
Can I take Veozah if I have a history of breast cancer?+–
Veozah does not contain hormones, which makes it relevant for women who have had hormone receptor–positive breast cancer and cannot use estrogen. Clinical data specifically for women with breast cancer history is limited; Astellas excluded this population from the core SKYLIGHT trials. Discuss the risk-benefit balance with your oncologist before starting.